GenVec to Present at the 14th Annual BIO CEO & Investor Conference

GAITHERSBURG, Md., Feb. 7, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC), a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a company overview highlighting recent developments at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 11:00 a.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay. The presentation will be available via webcast at http://www.veracast.com/webcasts/bio/ceoinvestor2012/91207182.cfm. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation may also be accessed via the investors and media section of the Company's Web site at http://ir.genvec.com/ under "Events & Presentations."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

SOURCE GenVec, Inc.